Inicio › Mieloma múltiple › Carolina del Norte
Ensayos clínicos de Mieloma múltiple en Carolina del Norte
53 estudios sobre Mieloma múltiple buscan participantes en Carolina del Norte.
Ciudades en Carolina del Norte
Texto oficial del estudio (inglés)
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- Novant Health Cancer Institute, Charlotte
- Forsythe Memorial Hospital Inc., dba Novant Health Oncology Specialists, Winston-Salem
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT07555938A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- University of North Carolina /ID# 251203, Chapel Hill
- Atrium Health Wake Forest Baptist Medical Center /ID# 251165, Winston-Salem
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 nov 2026 · NCT05650632A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- University of North Carolina at Chapel Hill, Chapel Hill
- Wake Forest University Health Sciences, Winston-Salem
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2026 · NCT05137054A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Levine Cancer Institute, Charlotte
ReclutandoFase 4
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT05201781A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
- Wake Forest University Baptist Medical Center (WFUBMC) - Comprehensive Cancer Center, Winston-Salem
ReclutandoFase 2
Edades de 18 a 80 · Todos los sexos · Actualizado el 3 nov 2026 · NCT07149857A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Levine Cancer Institute, Charlotte
- Novant Health, Charlotte
- Durham VAMC, Durham
- y 3 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT05552222A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
- Levine Cancer Institute, Charlotte
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT05652335A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- University of North Carolina, Chapel Hill
- Durham VAMC, Durham
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT07258511Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
- University of North Carolina Hospitals at Hillsborough, Chapel Hill
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 30 oct 2026 · NCT06433947A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- UNC Hospitals Adult Oncology Clinics, Chapel Hill
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 30 oct 2026 · NCT07284758A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- Duke Cancer Center, Durham
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 30 oct 2026 · NCT07280013A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Levine Cancer Institute, Charlotte
- Levine Cancer Institute, Charlotte
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 oct 2026 · NCT06615479Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
ReclutandoEstudio observacional
Edades de 18 a 120 · Todos los sexos · Actualizado el 28 oct 2026 · NCT01137643A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- Atrium Health Levine Cancer Institute /ID# 271510, Charlotte
- University Of North Carolina Health Care - Hillsborough Campus /ID# 272454, Hillsborough
- Atrium Health Wake Forest Baptist Medical Center /ID# 271294, Winston-Salem
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 27 oct 2026 · NCT06953960Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
- Levine Cancer Institute, Charlotte
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 26 oct 2026 · NCT04822337Neurocognitive Trajectories After BCMA CAR-T
- Atrium Health Levine Cancer, Charlotte
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 23 oct 2026 · NCT07740317A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- Atrium Health, Levine Cancer Institute, Charlotte
- Duke University Hospital, Durham
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 oct 2026 · NCT05651932Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study
- Wake Forest University, School of Medicine Dept. of Internal Medicine, Division of Hematology Oncology, Winston-Salem
ReclutandoFase 2
Edades de 60 en adelante · Todos los sexos · Actualizado el 22 oct 2026 · NCT06052826A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
- Research Site, Chapel Hill
- Research Site, Charlotte
- Research Site, Durham
- y 1 más
ReclutandoFase 3
Edades de 18 a 130 · Todos los sexos · Actualizado el 21 oct 2026 · NCT07735637A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
- University of North Carolina at Chapel Hill /ID# 274667, Chapel Hill
- Atrium Health Levine Cancer Institute /ID# 276193, Charlotte
- Atrium Health Wake Forest Baptist Medical Center /ID# 274847, Winston-Salem
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 19 oct 2026 · NCT06892522A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- University of North Carolina at Chapel Hill /ID# 277708, Chapel Hill
ReclutandoFase 2/3
Edades de 18 en adelante · Todos los sexos · Actualizado el 19 oct 2026 · NCT07095452Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Duke University, Durham
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 oct 2026 · NCT07648264AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Charlotte
- Research Site, Durham
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 8 oct 2026 · NCT05850234Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- University of North Carolina Medical Center, Chapel Hill
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 6 oct 2026 · NCT06297226A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Chapel Hill
- Research Site, Charlotte
- Research Site, Charlotte
- y 2 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT07391657A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Duke University Medical Center, Durham
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07518186A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
- Duke University Medical Center, Durham
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06500884A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
- Atrium Health Levine Cancer Institute, Charlotte
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 23 sept 2026 · NCT07116616TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Lineberger Comprehensive Cancer Center, Chapel Hill
- Atrium Health's Levine Cancer Institute, Charlotte
ReclutandoFase 2
Edades de 12 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT02693535HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
- Duke University Health System, Durham
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 sept 2026 · NCT06822972Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
- University of North Carolina Hospitals at Hillsborough, Hillsborough
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 ago 2026 · NCT06375044Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Southeastern Medical Oncology Center-Clinton, Clinton
- Southeastern Medical Oncology Center-Goldsboro, Goldsboro
- Southeastern Medical Oncology Center-Jacksonville, Jacksonville
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 19 ago 2026 · NCT04566328A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
- GSK Investigational Site, Chapel Hill
- GSK Investigational Site, Wilson
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 19 ago 2026 · NCT05714839DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill
Reclutando
Edades de 60 en adelante · Todos los sexos · Actualizado el 14 ago 2026 · NCT06296368Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Chapel Hill
- Research Site, Charlotte
- Research Site, Durham
- y 2 más
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 ago 2026 · NCT07764978Selinexor and Backbone Treatments of Multiple Myeloma Patients
- Duke Institute of Cancer/ Duke University, Durham
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 15 jul 2026 · NCT02343042Pre-malignant States to Hematologic Malignancies in Firefighters
- Levine Cancer Institute, Charlotte
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
Edades de 40 a 49 · Todos los sexos · Actualizado el 13 jul 2026 · NCT06870760CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
- Atrium Health Levine Cancer, Charlotte
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
Edades de 30 en adelante · Todos los sexos · Actualizado el 13 jul 2026 · NCT06644625A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
- University of North Carolina (Data Collection Only), Chapel Hill
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 6 jul 2026 · NCT06083922Registry of Older Patients With Cancer
- Seby B. Jones Cancer Center, Boone
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
- East Carolina University, Greenville
- y 4 más
ReclutandoEstudio observacional
Edades de 65 en adelante · Todos los sexos · Actualizado el 29 jun 2026 · NCT01137825De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.